Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin.
Proliferative vitreoretinopathy (PVR) remains the most common cause of failure in retinal detachment surgery. Surgical procedures for its repair entails complex and extensive instrumentation besides technical skill. The success rate varies widely with high incidence of redetachment. Keeping this in view, we evaluated the role of intravitreal daunorubicin as an anti-mitiotic agent in the inhibition of PVR. Our study concluded that 5 micrograms of intravitreal daunorubicin effectively inhibited PVR in the rabbit eye and the dosage was safe and nontoxic. The half-life of the drug was determined to be about 140 minutes, suggesting a prolonged intravitreal concentration sufficient to prevent fibroblast proliferation.
Kumar
A
A
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, AIIMS, New Delhi.
Tewari
H K
HK
Bathwal
D P
DP
Khosla
P K
PK
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D003630:Daunorubicin / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000633:toxicity; D004596:Electroretinography; D005347:Fibroblasts / Q000166:cytology; D005654:Fundus Oculi; D006207:Half-Life; D011817:Rabbits; D012160:Retina / Q000648:ultrastructure; D012163:Retinal Detachment / Q000150:complications*; D018630:Vitreoretinopathy, Proliferative / Q000188:drug therapy* / Q000209:etiology
D003630:Daunorubicin